5-FU-Induced Upregulation of Exosomal PD-L1 Causes Immunosuppression in Advanced Gastric Cancer Patients

Min Zhang(UC Irvine Health), Xiujuan Qu(First Hospital of China Medical University), Ti Wen(Nankai University), Chaoxu Zhang(First Hospital of China Medical University), Xiaofang Che(First Hospital of China Medical University), Shuo Wang(Shandong Institute of Automation), Ce Li(Affiliated Hospital of Hebei University), Yu Cheng(Hebei University), Kezuo Hou(First Hospital of China Medical University), Yunpeng Liu(Shenyang Institute of Automation), Yibo Fan(The University of Texas MD Anderson Cancer Center)
Frontiers in Oncology
April 22, 2020
10.3389/fonc.2020.00492
Cited by 53

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417